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Regulation of T-Cell Chemotaxis by Programmed
Death-Ligand 1 (PD-L1) in Dry Eye–Associated
Corneal Inflammation
Jaafar El Annan,1 Sunali Goyal,1 Qiang Zhang,1 Gordon J. Freeman,2 Arlene H. Sharpe,3
and Reza Dana1
PURPOSE. Given that dry eye disease (DED) is associated with T
cell–mediated inflammation of the ocular surface and that
PD-L1 is an important negative or inhibitory regulator of im-
mune responses constitutively expressed at high levels by
corneal epithelial cells, the authors studied the expression and
function of PD-L1 in DED.
METHODS. Dry eye was induced in untreated wild-type mice,
PD-L1/ mice, and wild-type mice treated with anti–PD-L1
antibody by exposing these mice to a desiccating environment
in the controlled environment chamber modified with subcu-
taneous administration of scopolamine. Real-time PCR was
used to quantify the expression of chemokine gene transcript
levels of multiple CC and CXC chemokine ligands and recep-
tors. Epifluorescence microscopy was used to evaluate corneal
infiltration of CD3 T cells after immunohistochemical stain-
ing.
RESULTS. The increased expression of specific chemokine li-
gands and receptors in PD-L1/ corneas of normal mice is
associated with significant increases in T-cell homing into these
corneas. Similar, and more enhanced, increases in T-cell infil-
tration were observed in PD-L1/ DED mice or DED mice
treated with anti–PD-L1 antibody compared with controls. In
addition, the authors found significantly decreased expression
of PD-L1 by corneal epithelial cells in DED and significantly
increased corneal fluorescein staining score with PD-L1 func-
tional blockade using anti–PD-L1 antibody.
CONCLUSIONS. Downregulation of corneal epithelial PD-L1 am-
plifies dry eye–associated corneal inflammation and epithe-
liopathy by increasing the expression of chemokine ligands
and receptors that promote T-cell homing to the ocular
surface. (Invest Ophthalmol Vis Sci. 2010;51:3418 –3423)
DOI:10.1167/iovs.09-3684
Dry eye disease (DED) affects many millions of persons, inparticular women, in the United States alone.1 The cur-
rent literature on the immunopathogenesis of DED focuses on
the inflammatory milieu of the tear film or conjunctiva,
whereas it is corneal inflammation that is the most clinically
recognizable and important ocular manifestation of DED.2–8
There is growing evidence that CD4 T cell–mediated inflam-
mation plays a critical role in amplifying the pathogenesis of
DED.9–15 Still, the manner by which this inflammation can
induce corneal pathology remains poorly understood.
PD-L1 is a member of the B7 family of receptors and has a
role in regulating T cell–mediated immunity.16 In vivo studies
using PD-L1/ mice and anti–PD-L1 blocking antibody have
provided evidence for the inhibitory functions of PD-L1 in both
autoimmunity and alloimmunity. For example, it has been
shown that tissue-specific PD-L1 expression protects against
autoimmune diabetes, ocular inflammation, and corneal allo-
graft rejection by inhibiting autoreactive and alloreactive T
cells.17–20 In DED, there is increased T-cell infiltration into the
conjunctiva, but, remarkably, the cornea remains relatively
resistant to this infiltration.9–13
Herein we test the hypothesis that decreased PD-L1 expres-
sion is associated with increased chemokine expression, in-
creased T-cell infiltration, and increased corneal fluorescein
staining. The purpose of the present study was to determine
the effect of PD-L1 on modulating the expression of chemokine
gene transcripts in the cornea. Additionally, we investigated
the potential role of PD-L1 in the pathogenesis of DED by
inducing DED in PD-L1/ mice and in mice treated with
anti–PD-L1 blocking antibody to determine how the blockade
or elimination of PD-L1 affects the expression of the principal
T-cell chemokines and the clinical aspects of DED.
MATERIALS AND METHODS
Mouse Model of Dry Eye
Eight- to 12-week-old female C57BL/6 mice were obtained from Tac-
onic Farms (Germantown, NY), and Charles River Laboratory (Boston,
MA). Similarly aged PD-L1/ C57BL/6 mice were generated as previ-
ously described.16 In all the experiments performed, the mice were
age-matched among the different groups. The protocol was approved
by the Institutional Animal Care and Use Committee, and all animals
were treated according to the ARVO Statement for the Use of Animals
in Ophthalmic and Vision Research. Dry eye was induced by place-
ment of mice in a controlled-environment chamber modified with
subcutaneous administration of scopolamine to maximize ocular dry-
ness as previously described.13–15,21,22 Age-matched mice not placed in
the controlled-environment chamber were used as controls.
PD-L1 Blockade
To block PD-L1–mediated signaling, five mice were treated 1 day
before dry eye induction and every other day thereafter for 10 days
with antimurine PD-L1 (10F.9G2, rat IgG2b; 150 g/mouse intraperi-
toneally) or control rat IgG (MP Biomedicals, Santa Ana, CA).17,23,24
Measurement of Corneal Fluorescein Staining
Corneal fluorescein staining was performed at baseline (day 0) and
then at days 2, 5, 7, and 9. One microliter of 2.5% fluorescein was
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applied to the lateral conjunctival sac of the mice, as previously
described.13–15,21,22 Eyes were examined for fluorescein staining after
5 minutes with a slit lamp biomicroscope under cobalt blue light.
Punctate staining was recorded in a masked fashion using the standard
National Eye Institute grading system. Each of the five areas of the
cornea was given a score from 0 to 3, with 0 denoting no epitheliopa-
thy and 3 denoting diffuse severe dry eye.25
Immunohistochemical Staining
The following antibodies were used for immunohistochemical stain-
ing: purified hamster anti–mouse CD3e monoclonal antibody (T-cell
marker, catalog no. 553057; isotype control purified hamster IgG1,
catalog no. 11121D) with a secondary antibody Cy-3 goat anti–Arme-
nian hamster antibody (catalog no. 127135–160). The primary anti-
body and isotype-matched control were purchased from BD PharMin-
gen, (San Diego, CA). The secondary antibody was purchased from
Jackson Laboratories (Bar Harbor, ME).
For cross-sectional staining of the cornea, whole eyeballs were
excised, frozen in OCT, cut into 7-m frozen sections, and fixed in
acetone for 15 minutes at room temperature. Immunostaining was
performed as described previously.13 Four to six eyeballs from four to
six mice per group were used for T-cell enumeration in the cornea.
Serial cross-sections per slide were studied under the epifluorescence
microscope (model E800; Nikon, Melville, NY) with a 40 objective
lens. Positively stained cells were counted in the stroma of the cornea
because the epithelium showed nonspecific background signal in all
the cross-sections investigated, including the isotype-matched con-
trols, over a length of 4 mm and to a depth of 100 m (the thickness
of the cornea). Results were expressed as the number of positive cells
per square millimeter.
RNA Isolation and RT-PCR
Corneas were harvested, and corneal epithelial layers were dissected as
described previously.26 Four to six corneas from four to six mice were
involved in each group. Each experiment was repeated three times. A
combined method for total RNA isolation was used, with reagent
(Trizol; Invitrogen Corp., Carlsbad, CA) for tissue homogenization on
ice, precipitation of RNA in the aqueous phase using 70% ethanol,
subsequent extraction, purification (RNeasy Micro Kit; Qiagen, Valen-
cia, CA), and storage at 80°C until future use. Fixed amounts of RNA
were reverse transcribed into cDNA with random hexamers (Super-
Script III Reverse Transcriptase; Invitrogen) according to the manufac-
turer’s protocol.
Real-time PCR
Quantitative PCR was performed (TaqMan Universal PCR Master Mix;
Applied Biosystems, Carlsbad, CA) with dye labeled predesigned prim-
ers (FAM-MGB; Applied Biosystems) for glyceraldehyde-3-phosphate
dehydrogenase GAPDH (Mm99999915_gl), programmed death-ligand
1 (PD-L1; Mm01208505_m1), CC chemokine receptor 5 (CCR5;
Mm01216171_ml), CXC chemokine receptor 3 (CXCR3; Mm004-
38269_ml), macrophage inflammatory protein 1 (MIP-1)/CCL3
(Mm00441258_ml), macrophage inflammatory protein 1 (MIP-1)/
CCL4 (Mm00443111_ml), regulated on activation, normal T-cell ex-
pressed and secreted (RANTES)/CCL5 (Mm01302428_ml), monokine
induced by IFN- (MIG)/CXCL9 (Mm00434946_ml), and IFN-–induc-
ible protein 10 (IP-10)/CXCL10 (Mm00444235_ml), according to the
manufacturer’s recommendation. PCR conditions were 2 minutes at
50°C and 10 minutes at 95°C, followed by 35 cycles of 15 seconds at
95°C and 60°C for 1 minute using a real-time PCR system (ABI Prism
7900 HT; Applied Biosystems). One microliter of cDNA was loaded in
each well, and assays were performed in duplicate. A nontemplate
control was included in all experiments to evaluate DNA contamina-
tion. Results of quantitative real-time PCR were analyzed by the com-
parative threshold cycle (CT) method and normalized to GAPDH as an
internal control.
Statistical Analysis
A two-tailed Student’s t-test was performed (Excel; Microsoft, Red-
mond, WA). P  0.05 was taken as indicative of statistical significance.
RESULTS
Increased T-Cell Homing and Expression of
Chemokines in PD-L1/ Corneas
The cornea is relatively unique in that it is largely resistant to
T-cell homing under normal conditions compared with many
other tissues (e.g., skin).27,28 To investigate the role of corneal
PD-L1 in inhibiting T-cell homing to the cornea under normal
conditions, we harvested globes from normal (non-dry eye)
PD-L1/ and wild-type (WT) mice and immunohistochemi-
cally stained cryosections for CD3 cells. We observed a sig-
nificant (15.7-fold) increase in CD3 T-cell homing to the
cornea (P  0.0002) in PD-L1/ compared with WT age-
matched mice (Fig. 1A).
T cells migrate and home to peripheral tissues along a
chemokine gradient.29 The increased homing of T cells into
the normal PD-L1/ cornea suggests that PD-L1 downregu-
lates the expression of chemokines/receptors in the cornea. To
evaluate this potential role of PD-L1, we compared the tran-
script level expression of chemokines/receptors in the cornea
and corneal epithelium of PD-L1/ with that of WT age-
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FIGURE 1. Increased T-cell infiltration and expression of chemokines
in normal corneas of PD-L1/ mice. (A) T-cell counting per square
millimeter of normal cornea in PD-L1/ compared with WT mice.
Each group consisted of four to six mice, and data represented the
mean  SEM. Real-time PCR analysis of chemokines (CXCR3, CXCL9,
CXCL10, CCR5, CCL5, CCL4, CCL3) in whole cornea (B) and corneal
epithelium (C) of normal PD-L1/ compared with normal WT mice
(defined as 1, dotted line). Each group consisted of four to six mice,
and data are representative of three independent experiments.
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matched mice by real-time PCR under normal conditions (Figs.
1B, 1C). We observed a marked increase in the expression level
of most chemokines/receptors in the cornea and corneal epi-
thelium of PD-L1/ compared with WT mice. This increase
was especially notable for CXCL9 (13-fold, cornea; nearly nine-
fold, corneal epithelium) and CCL5 (nearly fourfold, cornea;
nearly fivefold, corneal epithelium).
Decreased Expression of PD-L1 by Corneal
Epithelium in DED
Corneal epithelial PD-L1 plays an important role in suppressing
the corneal immune response.17 To investigate the expression
of PD-L1 in DED, we determined the transcript level of PD-L1
by the corneal epithelium by real-time PCR (Fig. 2A) at several
time points after DED induction. We observed a significant
(nearly fourfold) decrease at day 4 (P  0.001) and a greater
than twofold decrease at day 7 (P  0.049) in the transcript
level of PD-L1 by the corneal epithelium of WT mice in which
DED was induced compared with normal WT mice.
Enhanced Expression of Chemokines in DED
PD-L1/ Corneas
To investigate the role of PD-L1 in the pathogenesis of DED in
vivo, we induced DED for 10 days in PD-L1/ mice and
determined the expression levels of T-cell (both Th1 and Th2)
chemokines and their receptors in the cornea by real-time PCR
(Fig. 2B). We observed a marked increase in most of the
chemokines/receptors in the corneas of PD-L1/ DED com-
pared with WT DED age-matched mice. This increase was
especially notable for (MIG)/CXCL9 and (RANTES)/CCL5, with
161-fold and sevenfold increases, respectively.
To detect whether the increase in expression of these
chemokines/receptors was associated with increased T-cell
infiltration, we enumerated T cells infiltrating the cornea 10
days after DED induction (Figs. 2C, 2D), as described. We
observed a significant (more than 12-fold) increase in T cells
infiltrating the corneas (P  0.0001) of PD-L1/ DED com-
pared with WT DED age-matched mice. Significantly more of
these cells were CD4 T cells (data not shown).
Increased Expression of Chemokines in DED
Cornea after PD-L1 Blockade
To further investigate the in vivo function of PD-L1 in the
immunopathogenesis of DED, we induced DED for 10 days in
WT mice after systemic blockade of PD-L1 and determined the
expression of the chemokines/receptors in the cornea by real-
time PCR (Fig. 3A). We observed a marked increase in the
expression of most chemokines/receptors in the corneas of
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FIGURE 2. Decreased expression of PD-L1 and increased T-cell infiltration and expression of chemokines in DED. (A) Real-time PCR analysis of
PD-L1 transcript in the corneal epithelium of DED compared with normal WT mice at day 4 and day 7 after DED induction. Data represent the
mean  SEM and are representative of two independent experiments. (B) Real-time PCR analysis of chemokines (CXCR3, CXCL9, CXCL10, CCR5,
CCL5, CCL4, CCL3) in whole cornea of PD-L1/ DED compared with WT DED mice (defined as 1, dotted line). Each group consisted of four to
six mice, and data are representative of three independent experiments. (C) Representative micrographs of CD3 immunostaining of corneal
cross-sections showing increased T-cell infiltration (arrows) in PD-L1/ DED compared with WT DED mice. The epithelium shows nonspecific
background signal. Ep, epithelial layer; St, stromal layer; En, endothelial layer. (D) T-cell counting per square millimeter of cornea in PD-L1/ DED
compared with WT DED compared with WT normal mice. Each group consisted of four to six mice, and data represent the mean  SEM.
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DED mice after systemic blockade of PD-L1 in DED mice
compared with IgG (isotype)–treated DED age-matched mice.
This increase (nearly fourfold) was especially notable for
CXCL9 and CCL5.
To detect whether the increase in chemokines/receptors
expression was associated with increased T-cell infiltration, we
enumerated T cells infiltrating the cornea 10 days after DED
induction (Figs. 3B, 3C), as described. We observed a signifi-
cant (nearly sixfold) increase in T cells infiltrating the corneas
(P  0.0001) of anti–PD-L1 blocking antibody–treated DED
compared with IgG (isotype)–treated DED age-matched mice.
Increased Severity of DED after PD-L1 Blockade
The data above suggest that corneal epithelial PD-L1 is tightly
negatively correlated with the expression of chemokines and
chemokine receptors. To determine the functional relevance
of corneal epithelial PD-L1 on the clinical signs of DED, we
performed corneal fluorescein staining on DED mice treated
with anti–PD-L1 blocking antibody compared with IgG-treated
DED mice (Fig. 4). We observed a 40% increase in the CFS
score at day 2 (P 0.005), a 50% increase at day 5 (P 0.002),
a 70% increase at day 7 (P 0.0001), and a 40% increase at day
9 (P  0.0001) in the anti–PD-L1 blocking antibody–treated
mice compared with the IgG (isotype)–treated DED age-
matched mice, suggesting that inhibiting PD-L1 leads to signif-
icant exacerbation of DED.
DISCUSSION
We demonstrate here a novel function for PD-L1 in maintaining
peripheral immune tolerance by downregulating the expres-
sion of chemokine gene transcripts. In addition, we demon-
strate that in DED, one of the most common ophthalmic
conditions, PD-L1 expression is suppressed. We also examine
the functional significance of PD-L1 expression in DED by
studying DED pathogenesis using a blocking anti–PD-L1 mAb
and PD-L1/ mice showing that blockade or elimination of
PD-L1 is associated with amplified dry eye–associated inflam-
mation and overexpression of chemokines relevant for the
recruitment of T cells (Fig. 5).
We have previously shown that corneal epithelial cells con-
stitutively express high levels of PD-L1, which is capable of
directly suppressing the local T-effector response, contributing
to the immunoprivileged status of the cornea.17 Recently, it
was reported that an extremely low number of T cells may be
present in the cornea of the normal mouse.26 Interestingly, in
normal PD-L1/ mice, we found a significantly increased
number of T cells (compared with normal WT mice), compa-
rable to the numbers of T cells present in the dermis of the
normal skin of WT mice, which, unlike the cornea, has a
significant constitutive population of resident T cells and
which, unlike the cornea, has no detectable PD-L1 expression
in the uninflamed state.28,30–32
The increased infiltration of T cells into the corneas of
PD-L1/ mice suggested to us a potential role for PD-L1 in
regulating the expression of chemokines in the cornea. Ac-
cordingly, we determined the transcript levels of chemokines
and relevant receptors expressed by the cornea by real-time
PCR in normal PD-L1/ mice and normal WT mice. Interest-
ingly, we found a remarkable increase, primarily in the expres-
sion of CXCL9, CCL5, and their corresponding receptors in
PD-L1/ corneas. In the cornea, chemokines can be ex-
pressed by epithelial cells, keratocytes, immune cells, and
endothelial cells.33–35 In the PD-L1/ mice, most chemokines
are expressed by the epithelial cells because chemokine ex-
pression in the stroma/endothelium (which contains kerato-
cytes, immune cells, and endothelial cells) was below the
detectable level detected by real-time PCR (data not shown).
CXCL9 is an essential chemokine for corneal T-cell infiltra-
tion, as demonstrated in a murine model of HSV keratitis in
which CXCL9/ corneas are extremely resistant to T-cell
infiltration.36
Our data suggest that corneal PD-L1 expression is tightly
inversely correlated with the expression of major T-cell che-
mokine gene transcripts such as CXCL9. The mechanism by
which PD-L1 exerts its inhibitory function on chemokine ex-
pression requires further investigation. It is known that there
are two ligands for PD-L1, CD80 and PD-1. PD-1 is not ex-
pressed by the cornea, but CD80 is expressed at low levels
under normal conditions.17,37,38 CD80 expression is increased
in corneal antigen-presenting cells (Langerhans cells in the
corneal epithelium and dendritic cells in the corneal stroma)
under inflammatory conditions.37,38 Therefore, it is possible
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FIGURE 3. Increased T-cell infiltration and expression of chemokines
after PD-L1 blockade in DED. (A) Real-time PCR analysis of chemokines
(CXCR3, CXCL9, CXCL10, CCR5, CCL5, CCL4, CCL3) in whole cornea
of anti–PD-L1 blocking antibody–treated DED compared with IgG
(isotype)–treated DED mice (defined as 1, dotted line). (B) T-cell
counting per square millimeter of cornea in anti–PD-L1 blocking anti-
body–treated DED compared with IgG (isotype)–treated DED com-
pared with normal WT mice. Each group consisted of five mice, and
data represent the mean  SEM. (C) Representative micrographs of
CD3 immunostaining of corneal cross-sections with higher magnifica-
tion on the stroma showing increased T-cell infiltration (arrows) in
anti–PD-L1 blocking antibody–treated DED compared with IgG (iso-
type)–treated DED mice. St, stromal layer.
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that PD-L1 may exert its function by binding to CD80 in the
cornea or to an unidentified ligand on the corneal epithelium.
On the other hand, there are myriad questions to be deter-
mined, not the least of which is the precise receptor-ligand
interactions in the PD-L1 response system. Additionally, future
studies are clearly needed to determine the downstream PD-
L1–mediated signaling mechanisms that regulate chemokine
gene expression. In many chronic inflammatory and autoim-
mune diseases, IFN- leads to increased expression of PD-L1 by
parenchymal cells, which is believed to be a protective mech-
anism against T cell–mediated inflammation.39 Interestingly,
however, in DED, corneal expression of PD-L1 is suppressed,
thus disinhibiting chemokine expression normally afforded by
high constitutive expression of PD-L1. PD-L1/PD-1 or PD-L1/
CD80 interaction decreases the production of IFN- by T
cells.40 Hence, we propose that the decreased expression of
PD-L1 in DED corneas facilitates T-cell infiltration and IFN-
production in the cornea. In addition, in DED, the ocular
surface epithelial expression of molecules that inhibit T-cell
function is also suppressed.12 This suggests that the decreased
expression of the corneal immune privilege properties, such as
PD-L1, is a precedent step that promotes corneal T-cell infiltra-
tion and IFN- secretion in DED.
To further substantiate the role of PD-L1 in the pathogenesis
of DED in vivo, we induced DED in PD-L1/ mice and WT
mice treated with anti–PD-L1 blocking mAb and found a sig-
nificant increase in the expression levels of CXCL9 and CCL5
and relevant receptors. This was associated with a further
significant increase in T-cell infiltration into the corneas of
these mice and a significant increase in corneal fluorescein
staining score as a result of dry eye. The systemic administra-
tion of anti–PD-L1 antibody does not allow precise localization
of where this antagonism is effecting the immune response.
However, the data derived from both (normal and challenged)
PD-L1/mice strongly suggest that PD-L1 does in fact regulate
corneal immune response locally. In the aggregate, these data
suggest that the downregulation of corneal epithelial PD-L1
amplifies dry eye–associated corneal inflammation and epithe-
liopathy by modulating the expression of chemokine gene
transcripts, thus facilitating T-cell infiltration into the cornea in
DED (Fig. 5).
Data from several laboratories have strongly suggested that
tissue-specific expression of PD-L1 protects against autoim-
mune diseases, improves the success of tissue grafts, and pro-
motes immune quiescence.16–20 In addition, it has been shown
that the gene transfer or treatment with molecules that stimu-
lates PD-L1 signaling prolongs allogeneic and xenogeneic or-
gan transplant survival.41,42 However, the potential therapeu-
tic usefulness of overexpressing PD-L1, or PD-L1–mediated
signaling, in ocular disease remains unknown, although topical
blockade of corneal chemokine expression has been shown to
suppress inflammation in microbial keratitis and to promote
the survival of corneal transplants.43–45 Hence, our data not
only shed light on important immunoregulatory mechanisms in
dry eye disease, they suggest potentially novel therapeutic
strategies based on enhancing PD-L1 signaling (e.g., through
PD-L1 agonistic fusion protein).
FIGURE 4. Increased severity of
DED after PD-L1 blockade. Corneal
fluorescein scores were significantly
higher in anti–PD-L1 antibody–
treated mice compared with isotype
(IgG)–treated and untreated (DE)
mice during induction (day 2) and
during the progression phase of dis-
ease. n  5 mice in each group. P-
values between anti–PD-L1 anti-
body–treated compared with isotype
(IgG)–treated group at different time
points: day 2, P  0.005; day 5, P 
0.002; day 7, P  0.0001; day 9, P 
0.0001). Data represent the mean 
SEM.
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FIGURE 5. Conceptual figure summarizing proposed role of PD-L1 in
the pathogenesis of DED. Under normal conditions, the high constitu-
tive expression of PD-L1 by the corneal epithelium downregulates the
expression of chemokine gene transcripts and limits T-cell infiltration
into the cornea. In DED, the decreased expression of PD-L1 by the
corneal epithelium suppresses the regulatory effect of PD-L1 on
CXC/CC chemokine expression, which facilitates T-cell infiltration into
the cornea and further amplifies DED-associated inflammation.
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